UCB: creating value for patien ts. Company Overview Oct. 2017

Transcription

1 UCB: creating value for patien ts Company Overview Oct. 2017

2 UCB: reinventing itself, leveraging a solid heritage : Emmanuel Janssen establishes UCB in Brussels 1972: A new stateof-the-art R&D center in Brainel Alleud, Belgium 1990s: approval of Keppra, a novel anti-epileptic 2006: UCB acquires German pharma company Schwarz Pharma Combine leadership in antibody research & chemistry expertise to better treat severe diseases 1936: UCB enters the United States 1952: UCB discovers Atarax U.S. license awarded to Pfizer 1980s: UCB registers its novel antihistamine Zyrtec 2004: UCB acquires British biotech company Celltech Launch of Cimzia, Vimpat & Neupro Launch of a new anti-epileptic s 1990s Today Chemical Group Primary Care Pharma Specialty Bio-pharma

3 UCB: creating value for patients Bringing solutions to people living with neurological or immunological diseases 3 Key facts and figures 2016: Revenue: 4.2 billion rebitda: 1031 million More than 7500 employees globally Operations in ~40 countries R&D Spend: 24% of revenue Listed on Euronext

4 A global and diverse workforce 4 73 NATIONALITIES 50/50 MEN/WOMEN FY 2016 figures

5 3 core medicines for patients with severe diseases 5 Rheumatoid arthritis Psoriatic arthritis (PSA) Ankylosing spondylitis (AS) Axial spondyloarthritis (AxSpA) Crohn s disease Epilepsy Parkinson s disease Restless legs syndrome

6 Briviact (brivaracetam) 6 Our new anti-epileptic drug Quick facts Approved in Europe (Jan. 2016) and U.S. (Feb. 2016) as adjunctive therapy Received monotherapy label in the U.S. (Sep. 2017) Available in 12 countries Reached more than patients * worldwide Expected peak sales of at least 400 million ** * FY 2016 ** By 2026

7 Other key products 7 Keppra (levetiracetam) Epilepsy adjunctive therapy (also in monotherapy in Europe) Sold as E Keppra in Japan Keppra XR (levetiracetam Extended-release tablets) Epilepsy adjunctive therapy U.S. only Zyrtec (cetirizine HCl) Seasonal allergic rhinitis Xyzal (levocetirizine dihydrochloride) Allergies and chronic idiopatic urticaria

8 Drug Development timelines Compound Attrition Rates Production Scales 8 Lab Scale Pilot Scale Industrial Scale Early R&D 2-4Y Pre- Clinical 1Y Phase I Phase II Phase III Approval Market 1-2Y 2Y 2-3Y 1-2Y Total:9-12Y Compound Attrition

9 9 R&D investors in Europe The 2016 EU Industrial scoreboard by R&D intensity % (top 60) 26,0 24,0 22,0 20,0 18,0 16,0 14,0 12,0

10 10 R&D Investors Belgium (Millions )

11 A promising pipeline for differentiating solutions Evenity TM (romosozumab) osteoporosis UCB0942 (PPSI) highly drug resistant epilepsy dapirolizumab pegol (CD40L antibody) systemic lupus erythematosus bimekizumab (IL17 A/F) various skin and arthritis indications Phase 1 Phase 2 Phase 3 Filing Phase 2a results: Q Phase 2b results: H Partner: Biogen Phase 2b results: Q / Q Partner: Amgen 11 bimekizumab add-on to Cimzia rheumatoid arthritis seletalisib (PI3K delta inhibitor) immunology indications UCB7665 (anti-fcrn) immunology indications UCB1332 Parkinson s disease UCB4144 / VR942 asthma UCB6673 immunology indications UCB3491 epilepsy UCB7858 immunology indications Phase 2a results: Q Phase 2a results: Q Phase 2a results: Q Partner: Neuropore Partner: Vectura Partner: King s College London neurology immunology

12 Braine in 5 figures Braine Overview Eric Browaeys Site Director

13 964 13

14 54 14

15 500 15

16 40 16

17

18 BIO-PILOT GALENIC 18 PROCESS DEVLPT CHEMICAL PACKAGING R&D ADMIN

19 Green Strategy 19

20 20 Limit increase global temperature to well below 2 C Reduce CO2 emissions by at least 25% by 2030

21 CO2 Neutrality by 2075! Potential Scenarios (IPCC) 21 = «as is» = limiting temp rise to 2 C

22 Impact of Scenarios 22 AS IS 1900 Now : +-1 C + COP Now: +- 20cm +

23 UCB Strategy 23

24 Scope Scopes 1&2(66 kt) Scope 3 UCB Total footprint : 430 kt (2015 baseline) Neutrality scope: 175 kt (2015 baseline) 24 Our sites Transport Devices &Packaging Suppliers CMOs CARBON NEUTRALITY by 2030 BEST EFFORTS

25 UCB s 2015 Yearly Emissions = ~ 175 kt of CO2 (excluding CMOs & Suppliers) 25 8% 5% 4% Production sites Business travel (air) 30% Transport - Supply chain (estimated) 12% Fleet (estimated) Key Affiliates (incl Slough) 17% Employee Commuting (estimated) 24% Product end of life (packaging) Waste

26 UCB Emissions = 1 Airbus A380 in flight 24/24 26

27 Reduction Milestones % 100% 80% 95% 80% 65% RENEWABLE ENERGY ENERGY EFFICIENCY CHANGING BEHAVIOURS 60% 40% 20% 2020 : -5% 2025: -20% 2030: -35% 2050: -70% 30% 0%

28 Offsetting 28 Forests are Carbon Sinks: 1 Ha = 7 tons CO 2 /year

29 How? Right Balance between 29 Reduction and Offsetting 80% 20%

30 CO 2 Agenda to reach Carbon Neutrality by % 100% 80% 60% 95% 50% 80% 65% RENEWABLE ENERGY ENERGY EFFICIENCY CHANGING BEHAVIOURS 40% 30% 15% 20% 0% Scopes 1&2 0% 0% % Reduction Off setting Total -40% -60% -80% -45% -65% -65% REFORESTATION AVOIDING DEFORESTATION

31 31 What do we do already? Reduction

32 32 92% 55% in 2015

33

34 Cogeneration Principle Annual electrical production : +/- 5,000,000 [kw34h] Annual heat production : +/- 7,000,000 [kwh] CO2 savings : 1,000 tons/year (3% of Braine emissions) Investment: 1,500,000 Operational : Q ELECTRICITY 40% HEAT 90% 58%

35 Global Supply chain ACCOMPLISHMENTS 35 Intermodal Optimization

36 36

37 Fleet & Business Travel Number of vehicles >< Average CO² levels % Petrol + EV, HEV, PHEV: 1 January 2018 for BE; June 2018 for UK, DE, NL, US 0 ASIA UCB EUROPE UCB NORTH AMERICA UCB SOUTH AMERICA 0 Vehicle count Average CO2 Value Business Travel: we target a 30% reduction in 2018

38 Green Teams 38 = Self organized groups of employees located in Braine (8) and HQ working together to reduce their ecological footprint = 1200 Trees / Year for Belgium We will use recycled paper

39 39 What do we do already? Offsetting

40 2 projects of Reforestation: Virunga Park, DR Congo Ethiopia TCO2 by 2030 Partners: WWF CO2 Logic T CO2 by 2030 Partners: KUL We Forest Protecting the forests of the Virunga National Park

41 41 3 billion people in the world are still boiling their water and cooking their food on a fire between 3 stones Using cookstoves could save 50 to 70% of the wood they use and avoid deforestation

42 Avoid deforestation : Virunga Park, DR Congo TCO2 by 2030 Partners: WWF CO2 Logic Protecting the forests of the Virunga National Park

43 1 day UCB = 1 olympic swimming pool 43

44 100% 44

45 Our Environmental Commitments by % - 20% - 25%

46 Thanks!